Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,121 to 4,140 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| TICAGRELOR vs CLOPIDOGREL: Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding | 619 of 770 654 of 814 | 0.0 points -3.9 to 4.0 | 1,584 | NCT00391872 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome |
| TICAGRELOR vs CLOPIDOGREL: Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding | 329 of 770 341 of 814 | 0.8 points -4.0 to 5.7 | 1,584 | NCT00391872 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome |
| Pagibaximab vs Placebo: The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35. | 85 of 792 79 of 787 | 0.7 points -2.3 to 3.7 | 1,579 | NCT00646399 Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis |
| Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) vs Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood): All Cause Mortality at 6 Hours | 56 of 784 68 of 795 | -1.4 points -4.1 to 1.3 | 1,579 | NCT04704869 Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation |
| Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) vs Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood): Death From Bleeding at 6 Hours | 32 of 784 35 of 795 | -0.3 points -2.4 to 1.7 | 1,579 | NCT04704869 Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation |
| Dabigatran 220mg vs Enoxaparin: Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period | 61 of 792 69 of 786 | -1.1 points -3.8 to 1.7 | 1,578 | NCT00657150 Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty |
| Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) vs Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood): All Cause Mortality at 24 Hours | 88 of 783 97 of 794 | -1.0 points -4.2 to 2.2 | 1,577 | NCT04704869 Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation |
| Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) vs Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood): Death From Bleeding at 24 Hours | 43 of 783 39 of 794 | 0.6 points -1.6 to 2.8 | 1,577 | NCT04704869 Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation |
| Abatacept (LT) vs Abatacept (ST): serious adverse events | 61 of 530 110 of 1,046 | 1.0 points -2.2 to 4.4 | 1,576 | NCT00124982 Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy |
| Dabigatran 220mg vs Enoxaparin: Number of Participants With Total Deep Vein Thrombosis During Treatment Period | 60 of 791 67 of 784 | -1.0 points -3.7 to 1.7 | 1,575 | NCT00657150 Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty |
| Regional Anesthesia vs General Anesthesia: Inpatient Mortality | 5 of 782 13 of 790 | -1.0 points -2.2 to 0.1 | 1,572 | NCT02507505 Regional Versus General Anesthesia for Promoting Independence After Hip Fracture |
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE) | 267 of 785 206 of 787 | 7.8 points 3.3 to 12.3 | 1,572 | NCT03675737 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) |
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Experienced an Adverse Event (AE) | 776 of 785 771 of 787 | 0.9 points -0.4 to 2.2 | 1,572 | NCT03675737 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) |
| 10% Povidone-iodine (1% Free Iodine) in Purified Water vs 4% Chlorhexidine Gluconate (CHG) in Purified Water: Number of Participants With a Deep Incisional or Organ/Space Infection | 46 of 787 51 of 784 | -0.7 points -3.1 to 1.7 | 1,571 | NCT03385304 Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures |
| 10% Povidone-iodine (1% Free Iodine) in Purified Water vs 4% Chlorhexidine Gluconate (CHG) in Purified Water: Number of Participants With a Superficial Incisional Surgical Site Infection (SSI) | 13 of 787 7 of 784 | 0.8 points -0.4 to 2.0 | 1,571 | NCT03385304 Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures |
| Roflumilast vs Placebo: serious adverse events | 157 of 778 183 of 790 | -3.0 points -7.1 to 1.1 | 1,568 | NCT00297115 Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125) |
| Esketamine Nasal Spray (IND Phase) vs Esketamine Nasal Spray (OP/MA Phase): Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 346 of 458 1,052 of 1,110 | -19.2 points -23.5 to -15.2 | 1,568 | NCT02782104 A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression |
| Esketamine Nasal Spray (IND Phase) vs Esketamine Nasal Spray (OP/MA Phase): deaths from any cause | 1 of 458 8 of 1,110 | -0.5 points -1.2 to 0.6 | 1,568 | NCT02782104 A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression |
| Esketamine Nasal Spray (IND Phase) vs Esketamine Nasal Spray (OP/MA Phase): serious adverse events | 5 of 458 212 of 1,110 | -18.0 points -20.5 to -15.4 | 1,568 | NCT02782104 A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression |
| Pravastatin Group vs Control Group: serious adverse events | 188 of 780 164 of 785 | 3.2 points -0.9 to 7.3 | 1,565 | NCT00221104 Japan Statin Treatment Against Recurrent Stroke (J-STARS) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=207"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=207
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00391872-2036f827",
"title": "TICAGRELOR vs CLOPIDOGREL: Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding",
"summary": "619 of 770 against 654 of 814; risk difference 0.0 points, 95% interval -3.9 to 4.0; NCT00391872, A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome",
"record": "/library/comparisons/NCT00391872-2036f827",
"nct_id": "NCT00391872",
"kind": "outcome",
"participants": 1584,
"risk_difference": {
"value": 0.00045630045630040694,
"lower": -0.03878350983653005,
"upper": 0.03952284529313485
},
"group_1": "619 of 770",
"group_2": "654 of 814",
"difference": "0.0 points",
"interval": "-3.9 to 4.0",
"trial_title": "A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome"
},
{
"id": "NCT00391872-f0fb560f",
"title": "TICAGRELOR vs CLOPIDOGREL: Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding",
"summary": "329 of 770 against 341 of 814; risk difference 0.8 points, 95% interval -4.0 to 5.7; NCT00391872, A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome",
"record": "/library/comparisons/NCT00391872-f0fb560f",
"nct_id": "NCT00391872",
"kind": "outcome",
"participants": 1584,
"risk_difference": {
"value": 0.008353808353808334,
"lower": -0.04021889635098807,
"upper": 0.05691437205124145
},
"group_1": "329 of 770",
"group_2": "341 of 814",
"difference": "0.8 points",
"interval": "-4.0 to 5.7",
"trial_title": "A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=208",
"request_id": "PExbif8P5Wkx9CrJ"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant